NCT00682032Recruiting
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 10 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 19 May 2008
- Start date
- Oct 2008
- Primary completion date
- Apr 2025
- Lead sponsor
- University of Louisville
- Diseases
- Lung cancer
- NCT number
- NCT00682032
What you commit to
- Study type: Interventional
- Planned participants: 300
- From Oct 2008 to the primary completion date, Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
- currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
Other illness
- history of hypersensitivity reactions attributed to beta-glucan
- presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- AIM 3:
- history of hypersensitivity reactions attributed to beta-glucan
- presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Who the study is looking for
- suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
- treatment naive or no treatment within 6 months prior to enrollment
- able to swallow pills
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
- absolute neutrophil count (ANC) at least 1500/microl
- able to understand and willing to sign a written informed consent document
- resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon
- treatment naive
- able to swallow pills
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- must be an operative candidate
- absolute neutrophil count (ANC) at least 1500/microl
- able to understand and willing to sign a written informed consent document
Criteria the registry did not label
- AIM 2:
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| James Graham Brown Cancer Center Coordinator of this site? Confirm its status | Louisville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.